IMTX -
Immatics N.V. Ordinary Shares
| Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
| 9.5 0.68 (7.16%) |
--- |
0.0 (0.0%) |
-0.01 (-0.05%) |
0.6 (6.32%) |
0.1 (0.99%) |
--- |
0.6 (6.32%) |
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
Earnings & Ratios
- Basic EPS:
- Diluted EPS:
- Basic P/E:
- Diluted P/E:
- RSI(14) 1m:
- 49.55
- VWAP:
- 10.18
- RVol:
Events
| Period |
Kind |
Movement |
Occurred At |
Related News
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress
Dec 11, 2025 12:00
Immatics Announces $125 Million Underwritten Offering
Dec 05, 2025 11:00
Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps
Nov 12, 2025 12:00
Immatics Appoints Venkat Ramanan as Chief Financial Officer
Oct 01, 2025 11:00
TCR Therapy Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Developing Drugs for the Market Entry | DelveInsight
Mar 06, 2025 18:00
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
Nov 08, 2024 22:00
Immatics Announces Pricing of $150 Million Public Offering
Oct 11, 2024 00:50
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
Oct 04, 2024 13:00
Immatics Announces Second Quarter 2024 Financial Results and Business Update
Aug 13, 2024 11:00
Memo Therapeutics AG appoints Paul Carter as Chairperson - GlobeNewswire
Jul 08, 2024 06:02